

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/723,207
				Filing Date	11/24/2003
				First Named Inventor	Chang Yi Wang
				Art Unit	1644
				Examiner Name	Nora M. Rooney
Sheet	1	of	4	Attorney Docket Number	1004263.125US (1151-4153US2)

Non Patent Literature Documents			
Examiner Initial	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1.	ABAZA, M.-S. et al., "Effects of Amino Acid Substitutions Outside an Antigenic Site on Protein Binding to Monoclonal Antibodies of Predetermined Specificity Obtained by Peptide Immunization: Demonstration with Region 94-100 (Antigenic Site 3) of Myoglobin", <u>Journal of Protein Chemistry</u> , 11(5): 433-444, 1992.	<input type="checkbox"/>
	2.	ALEXANDER, J. et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides", <u>Immunity</u> , 1: 751-761, 1994.	<input type="checkbox"/>
	3.	BABBITT, B.P. et al., <u>Nature</u> , 317: 359-361, 1985.	<input type="checkbox"/>
	4.	BRETT, S.J. et al., <u>Eur. J. Immunol.</u> , 23: 1608-1614, 1993.	<input type="checkbox"/>
	5.	BURT, D.S. et al., "Inhibition of Binding of Rat IgE to Rat Mast Cells By Synthetic IgE Peptides", <u>Eur. J. Immunol.</u> , 17: 437-440, 1987.	<input type="checkbox"/>
	6.	BURT, D. S. et al., "Analysis of the Interaction Between Rat Immunoglobulin E and Rat Mast Cells Using Anti-Peptide Antibodies", <u>Molecular Immunology</u> , 24(4): 379-389, 1987.	<input type="checkbox"/>
	7.	CEASE, K.B., <u>Intern. Rev. Immunol.</u> , 7:85-107, 1990.	<input type="checkbox"/>
	8.	DAVIS, F.M. et al., "Can Anti-IgE Be Used to Treat Allergy?", <u>Springer Seminars In Immunopathology</u> , 15: 51-73, 1993.	<input type="checkbox"/>
	9.	DORRINGTON, K.J. et al., <u>Immunol. Rev.</u> , 41: 3-25, 1978.	<input type="checkbox"/>
	10.	ELDRIDGE, J.H. et al., "Biodegradable Microspheres As A Vaccine Delivery System", <u>Molecular Immunology</u> , 28(3): 287-294, 1991.	<input type="checkbox"/>
	11.	FERRARI, C., et al., "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen", <u>J. Clin. Invest.</u> , 88: 214-222, July 1991.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/723,207
				Filing Date	11/24/2003
				First Named Inventor	Chang Yi Wang
				Art Unit	1644
				Examiner Name	Nora M. Rooney
Sheet	2	of	4	Attorney Docket Number	1004263.125US (1151-4153US2)

Non Patent Literature Documents				
Examiner Initial	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	12.	GHADERI, A.A. et al., "Epitope Mapping of the Site(s) of Binding of FcεRII/CD23 Within Human IgE. Determination of the B Lymphocyte-Binding Sites by Use of Synthetic Peptides and Anti-Peptide Antibodies Representative of Linear Fc Sequences", <u>Molecular Immunology</u> , 30(18): 1655-1663, 1993.		<input type="checkbox"/>
	13.	GRANT, G.A., Washington University School of Medicine, 61-67 and 281, 1992.		<input type="checkbox"/>
	14.	HABA, S. et al., "Inhibition of IgE Synthesis by Anti-IgE: Role in Long-Term Inhibition of IgE Synthesis by Neonatally Administered Soluble IgE", <u>Proc. Natl. Acad. Sci. USA</u> , 87: 3363-3367, May 1990.		<input type="checkbox"/>
	15.	HARLOW, E. et al., <u>Antibodies- A Laboratory Manual</u> , published by Cold Spring Harbor Laboratory, 82-83 and 128-129, 1988.		<input type="checkbox"/>
	16.	HELM, B. et al., "The Mast Cell Binding Site on Human Immunoglobulin E", <u>Nature</u> , 331: 180-183, January 14, 1988.		<input type="checkbox"/>
	17.	HELM, B.A. et al., <u>Eur. J. Immunol.</u> , 21: 1543-1548, 1991.		<input type="checkbox"/>
	18.	HELLMAN, L., <u>Eur. J. Immunol.</u> , 24: 415-420, 1994.		<input type="checkbox"/>
	19.	HEUSSER, C. et al., "Therapeutic Potential of Anti-IgE Antibodies", <u>Current Opinion in Immunology</u> , 9(6): 805-813, December 1997.		<input type="checkbox"/>
	20.	KUBY, J., "Antigens", <u>Immunology</u> , Second Edition, 85-96, 1994.		<input type="checkbox"/>
	21.	MACGLASHAN, D.W., Jr. et al., "Down-Regulation of FcεRI Expression on Human Basophils During in Vivo Treatment of Atopic Patients with Anti-IgE Antibody", <u>J. of Immunol.</u> , 1438-1445, 1997.		<input type="checkbox"/>
	22.	MCDONNELL, J.M. et al., <u>Biochemical Society Transactions</u> , 25:387-392, 1997.		<input type="checkbox"/>
	23.	MEISTER, G.E. et al., "Two Novel T Cell Epitope Prediction Algorithms Based on MHC-Binding Motifs; Comparison of Predicted and Published Epitopes from Mycobacterium Tuberculosis and HIV Protein Sequences", <u>Vaccine</u> , 13(6): 581-591, 1995.		<input type="checkbox"/>

Examiner	Date Considered
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/723,207
				Filing Date	11/24/2003
				First Named Inventor	Chang Yi Wang
				Art Unit	1644
				Examiner Name	Nora M. Rooney
Sheet	3	of	4	Attorney Docket Number	1004263.125US (1151-4153US2)

Non Patent Literature Documents				
Examiner Initial	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	24.	NAVARRO, P. et al., "The Complete cDNA and Deducted Amino Acid Sequence of Equine IgE", <u>Molecular Immunology</u> , 32(1): 1-8, 1995.		<input type="checkbox"/>
	25.	NGO, J.T. et al., "Protein Folding Problem and Tertiary Structure Prediction", in: <u>The Protein Folding Problem and Tertiary Structure Prediction</u> , Merz, Jr., K. and Le Grand, S., eds., Birkhauser, Boston, Massachusetts, pp. 491-495 (1994)		<input type="checkbox"/>
	26.	NIO, J., et al., "Inhibition of Passive Sensitization of Human Peripheral Basophils by Synthetic Human Immunoglobulin E. Peptide Fragments", <u>FEBS</u> , 319(3): 225-228, March 1993.		<input type="checkbox"/>
	27.	NIO, N. et al., "Inhibition of Allergic Responses by Synthetic Immunoglobulin E Peptide Fragments and the Delineation of the Binding Sites in the Immunoglobulin E Molecule to the Fc Receptor", <u>Peptide Chemistry</u> , 765-768, 1987.		<input type="checkbox"/>
	28.	NIO, N. et al., "Inhibition of Passive Cutaneous Anaphylaxis by Synthetic Human Immunoglobulin E Peptide Fragments", <u>FEBS Letters</u> , 314(3): 229-231, December 1992.		<input type="checkbox"/>
	29.	NISSIM, A. et al., "Fine Specificity of the IgE Interaction with the Low and High Affinity Fc Receptor", <u>The Journal of Immunology</u> , 150(4), 1365-1374, February 15, 1993.		<input type="checkbox"/>
	30.	PARTIDOS, C.D. et al., "Immune Responses in Mice Following Immunization with Chimeric Synthetic Peptides Representing B and T Cell Epitopes of Measles Virus Proteins", <u>Journal of General Virology</u> , 72: 1293-1299, 1991.		<input type="checkbox"/>
	31.	PRESTA, L. et al., "The Binding Site on Human Immunoglobulin E for Its High Affinity Receptor", <u>The Journal of Biological Chemistry</u> , 269(42): 26368-26373, October 21, 1994.		<input type="checkbox"/>
	32.	PRESTA, L.G. et al., "Humanization of an Antibody Directed Against IgE", <u>Journal of Immunology</u> , 151(5): 2623-2632, September 1, 1993.		<input type="checkbox"/>
	33.	ROBERTSON, M.W. et al., <u>Molecular Immunol.</u> , 25: 103-113, 1988.		<input type="checkbox"/>

Examiner	Date Considered
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/723,207
				Filing Date	11/24/2003
				First Named Inventor	Chang Yi Wang
				Art Unit	1644
				Examiner Name	Nora M. Rooney
Sheet	4	of	4	Attorney Docket Number	1004263.125US (1151-4153US2)

Non Patent Literature Documents			
Examiner Initial	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	34.	ROTHBARD, J.B. and Taylor, W.R., "A sequence pattern common to T cell epitopes", <u>The EMBO Journal</u> , 7(1): 93-100, 1988	<input type="checkbox"/>
	35.	RUDOLF, M.P. et al., "Effect of Anti-IgE Antibodies on FcεRI-Bound IgE", <u>Journal of Immunology</u> , 157: 5646-5652, 1996.	<input type="checkbox"/>
	36.	RUDOLF, M.P. et al., <u>Journal of Immunology</u> , 160: 3315-3321, 1998.	<input type="checkbox"/>
	37.	SCHUTZE, M-P. et al., "Carrier-Induced Epitopic Suppression, A Major Issue for Future Synthetic Vaccines", <u>Journal of Immunology</u> , 135(4): 2319-2322, October 1985.	<input type="checkbox"/>
	38.	STADLER, B.M. et al., "Anti-IgE In Allergic Sensitization", <u>Immunology and Cell Biology</u> , 74: 195-200, 1996.	<input type="checkbox"/>
	39.	STAGG, A.J. et al., "Primary Human T-Cell Responses To The Major Outer Membrane Protein of Chlamydia trachomatis", <u>Immunol.</u> , 79, 1-9, 1993.	<input type="checkbox"/>
	40.	TAM, J. P., "Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system", <u>PNAS</u> , 85:5409-5413, 1988	<input type="checkbox"/>
	41.	VERCELLI, D., et al., "The B-Cell Binding Site on Human Immunoglobulin E", <u>Nature</u> , 338,: 649-651, April 20, 1989.	<input type="checkbox"/>
	42.	WANG, C.Y., et al., "Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen", <u>Science</u> , 254(5029): 285-288, 1991	<input type="checkbox"/>
	43.	International Search Report from related International Application PCT/US99/13959 filed June 21, 1999	<input type="checkbox"/>

Examiner	Date Considered
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.